logo
Crozer Health closure: Hundreds attend Delaware County job fair

Crozer Health closure: Hundreds attend Delaware County job fair

Yahoo14-05-2025
The Brief
A job fair was held in Delaware County aimed at connecting thousands of workers impacted by the Crozer Health bankruptcy and eventual closure to new careers.
More than 200 employers and support systems lined up in Subaru Park in Chester for them Tuesday.
CHESTER, Pa. - Hundreds of former employees of Crozer Health attended a job fair at Subaru Park, in Chester, in order to help those impacted move on in new positions and careers.
Personal impacts
Michael Payne walked through Subaru Park in Chester with fellow former OR Surgical Technologists on Tuesday, joining the thousands affected by recent Crozer Health layoffs, trying to find a new full-time job.
He says the layoff couldn't have come at a worse time.
"My wife had a stroke maybe three to four weeks prior to me losing my job. She was on my benefits, my children is on my benefits and everything got ripped from under me," he says. "I'm praying, I'm praying to God that I land something."
Kareeman Blagman, also a OR Surgical Technologist, says they were hopeful until their last day.
"It felt like a death," she says. "My ideal next job would just be somewhere that's more stable, just working at another great facility and learning."
What we know
More than 200 employers set up around the concourse for the four-hour job fair, a collaboration between the Delaware County Workforce Development Office, PA CareerLink® Delaware County, Pa. Department of Labor & Industry, and numerous community partners.
Michael Robinson, with Outreach and Hiring at Temple University, was among the many also offering free resources.
"Resume writing, job referrals, we help them with their job search tactics," he says. "There's a lot of people as you can see looking for work."
Dr. Monica Taylor, Chair of Delaware County Council, says for those that could not make the job fair, their transition center for laid-off employees will remain open 8:30 to 5:00 p.m., Monday through Friday, at 160 E. 7th Street in Chester. You can make an appointment by calling (610) 876-4855, and walk-ins are also allowed.
"You can't replace a Crozer and some of our employees have been here serving our community for decades, but I do feel like today is the next step. People are starting to look at what the next opportunity is," she says.
What's next
As for next steps for healthcare in Delaware County, she says they are continuing to work with non-profit providers in the region.
Mayor of Chester, Stefan Roots, also stopped by.
"We're very hopeful that when the smoke clears, the building is still there intact, the need is certainly intact, and anyone that wants to bring a health system to Chester, believe me, I'm rolling out the red carpet," he says.
Payne, while praying and hopeful for a new full-time gig, says he is also worried about the community.
"People can die and that's my main concern," he says. "Hopefully it helps the people that lost their jobs, but for the community, it's still sad, it's a terrible thing."
Information for Crozer workers
County officials say Crozer employees can text 'healthjobs' to 888777 for updates from PA CareerLink or visitwww.pacareerlinkdelco.org/crozer-former-employees for career and training events and resources.
Employees can also sign up for virtual sessions starting April 30 for more information about unemployment, health insurance and training services, or drop by the Crozer Transition Center/PA CareerLink at 160 E 7th St. in Chester starting on May 5 from 8:30 a.m. to 5 p.m. Evening and weekend hours to be announced later.
Scan the QR code for career and training events:
Mental health support
Those in need can also utilize the National Suicide & Crisis Hotline and call, text or chat 988. For mental health support from Peer, contact the Peer Warmline at 855-464-9342. You can also reach the Delaware County Crisis Connections Team at 1-855-889-7827.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

OR Royalties: Q2 Earnings Snapshot
OR Royalties: Q2 Earnings Snapshot

San Francisco Chronicle​

time05-08-2025

  • San Francisco Chronicle​

OR Royalties: Q2 Earnings Snapshot

MONTREAL (AP) — MONTREAL (AP) — OR Royalties Inc. (OR) on Tuesday reported second-quarter net income of $23.4 million. The Montreal-based company said it had net income of 12 cents per share. Earnings, adjusted for non-recurring costs, were 13 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 17 cents per share. The mining royalty and exploration company posted revenue of $43.6 million in the period. _____

Hearing set after Prospect Medical asks judge to "abandon" shuttered 2 Delaware County hospitals
Hearing set after Prospect Medical asks judge to "abandon" shuttered 2 Delaware County hospitals

CBS News

time30-07-2025

  • CBS News

Hearing set after Prospect Medical asks judge to "abandon" shuttered 2 Delaware County hospitals

A hearing is set for Monday after attorneys for Prospect Medical Holdings asked a bankruptcy court judge to allow the company to "abandon" the shuttered Delaware County Memorial and Taylor hospitals in Pennsylvania. In court papers, attorneys for Prospect say offers by outside parties to purchase the closed hospitals are far below liabilities on the properties. They described the real estate as "under water." CBS News Philadelphia reviewed tax records, revealing nearly $20 million in delinquent taxes on the properties in Ridley Park and Upper Darby. A spokesperson for Prospect did not return our request for comment. The Upper Darby School District had expressed interest in the Delaware County Memorial Hospital property, which closed in 2022. A district spokesperson said they continue to explore options with the hospital property. Prospect is the parent company of Crozer Health, which shut down Taylor and Crozer Chester Medical Center this past spring. More than 2,000 employees were laid off.

Adrenocortical Carcinoma Market Forecast upto 2034—Insights into Emerging Therapies and Market Trends
Adrenocortical Carcinoma Market Forecast upto 2034—Insights into Emerging Therapies and Market Trends

Business Upturn

time29-07-2025

  • Business Upturn

Adrenocortical Carcinoma Market Forecast upto 2034—Insights into Emerging Therapies and Market Trends

New York, USA, July 29, 2025 (GLOBE NEWSWIRE) — Adrenocortical Carcinoma Market Forecast upto 2034—Insights into Emerging Therapies and Market Trends | DelveInsight The adrenocortical carcinoma market in the 7MM is anticipated to boost during the forecast period (2025–2034), due to the launch of emerging therapies such as CY‑101 from Cytovation and OR‑449 from Orphagen Pharmaceuticals, and others, and the increasing cases of ACC. DelveInsight's Adrenocortical Carcinoma Market Insights report includes a comprehensive understanding of current treatment practices, emerging adrenocortical carcinoma drugs, market share of individual therapies, and current and forecasted adrenocortical carcinoma market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Adrenocortical Carcinoma Market Report According to DelveInsight's analysis, the total adrenocortical carcinoma market size is expected to grow from USD 30 million in the 7MM in 2024. in the 7MM in 2024. The United States accounts for the largest market size of adrenocortical carcinoma, in comparison to EU4 (Germany, Italy, France, and Spain) and the UK, and Japan. Based on DelveInsight's assessment in 2024, the 7MM had 1,250 incident cases of ACC, and it is projected that these cases will experience an increasing growth trend with a significant CAGR during the forecast period (2025−2034). incident cases of ACC, and it is projected that these cases will experience an increasing growth trend with a significant CAGR during the forecast period (2025−2034). Prominent companies, including GlaxoSmithKline, Bristol Myers Squibb, Merck, Cytovation, Enterome, Orphagen Pharmaceuticals, and others, are actively working on innovative adrenocortical carcinoma drugs. and others, are actively working on innovative adrenocortical carcinoma drugs. Some of the key adrenocortical carcinoma therapies in the pipeline include CY-101, OR-449, dostarlimab, nivolumab + ipilimumab, and pembrolizumab, EO2401 + Nivolumab, and others. These novel adrenocortical carcinoma therapies are anticipated to enter the adrenocortical carcinoma market in the forecast period and are expected to change the market. Discover which adrenocortical carcinoma medications are expected to grab the market share @ Adrenocortical Carcinoma Market Report Adrenocortical Carcinoma Market Dynamics The adrenocortical carcinoma market dynamics are anticipated to change in the coming years. The availability of surgical options such as adrenalectomy provides a practical approach for removing the diseased adrenal gland, thereby improving access to treatment. Mitotane remains the mainstay treatment for ACC, with its exclusive status as an 'Off-Patent, Off-Exclusivity Drug without an Approved Generic' in the Orange Book reinforcing its dominant position. There is significant potential for collaboration among medical professionals, researchers, and patient advocacy organizations to raise disease awareness and broaden access to care. The limited therapeutic landscape for ACC presents a strategic opportunity for new players to enter and expand within the market. Furthermore, many potential therapies are being investigated for the treatment of adrenocortical carcinoma, and it is safe to predict that the treatment space will significantly impact the adrenocortical carcinoma market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the adrenocortical carcinoma market in the 7MM. However, several factors may impede the growth of the adrenocortical carcinoma market. The reliance on surgery as the main treatment for ACC, due to the limited availability of systemic therapies, highlights a weakness stemming from a lack of diverse treatment options. ACC's rarity and the small number of affected patients make it difficult to conduct large-scale clinical trials, complicating the development of evidence-based treatment protocols and assessment of new therapies. Resistance to current treatments like mitotane monotherapy, or their limited effectiveness, often leads to poor patient outcomes and represents a major challenge. Additionally, the ultra-rare nature of ACC limits access to funding and resources for research and development, posing a significant barrier to progress. Moreover, adrenocortical carcinoma treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the adrenocortical carcinoma market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the adrenocortical carcinoma market growth. Adrenocortical Carcinoma Treatment Market Surgical removal is the primary treatment option for localized adrenocortical carcinoma. However, many patients are diagnosed at advanced stages, where surgery alone is unlikely to be curative. Chemotherapy, particularly mitotane, is the only FDA-approved drug for ACC, though its effectiveness varies, and it often causes substantial side effects. Complete surgical excision remains the only potentially curative option. For localized cases, adjuvant therapies are used to reduce the risk of recurrence. In cases where the tumor is unresectable or has metastasized, treatment shifts to palliative care. First-line treatment strategies for ACC are personalized, taking into account the patient's prognostic profile. For those with good performance status and aggressive disease, a combination regimen like EDP-M (etoposide, doxorubicin, cisplatin, and mitotane) is often employed. Patients with less aggressive disease may be treated with mitotane alone, sometimes alongside locoregional interventions. Despite some efficacy, EDP-M is not curative, and the overall prognosis remains poor. Second-line options such as streptozocin with mitotane (S+M) and gemcitabine with capecitabine (G+C) show limited effectiveness, with response rates around 10%. G+C is generally well tolerated but lacks strong molecular predictors of response. Temozolomide, used as a third-line option, shows anti-cancer activity in laboratory settings. While some patients experience disease stabilization, its clinical benefit is modest, and research is ongoing to determine which patient subgroups may respond best. Looking ahead, future treatment advances may include new chemotherapies, angiogenesis inhibitors, and targeted small-molecule drugs. These innovations, driven by deeper molecular insights into ACC biology, offer potential for improved therapeutic outcomes. Learn more about the adrenocortical carcinoma treatment options @ Adrenocortical Carcinoma Drugs Market Adrenocortical Carcinoma Emerging Drugs and Companies Research and development efforts in adrenocortical carcinoma remain limited due to its classification as an ultra-rare disease, resulting in a sparse pipeline with only a few therapies currently in Phase II, Phase I/II, or preclinical stages. Among the investigational treatments being evaluated in clinical trials are Dostarlimab (GlaxoSmithKline), the combination of Nivolumab and Ipilimumab (Bristol Myers Squibb), Pembrolizumab (Merck), CY-101 (Cytovation), EO2401 combined with Nivolumab (Enterome/Bristol Myers Squibb), OR-449 (Orphagen Pharmaceuticals), and others. CY-101 is designed to selectively attack and destabilize cancer cell membranes, which leads to the release of tumor-specific neoantigens and enables the immune system to launch a targeted, systemic response against the cancer. In addition, CY-101 blocks the β-catenin signaling pathway, thereby impeding tumor progression and further activating immune defenses. Currently being developed by Cytovation, CY-101 is slated to enter a multi-national Phase II clinical trial for adrenocortical carcinoma in late 2025, with initial data expected in 2026. This study is being conducted in collaboration with Cancer Research UK and the Norwegian Cancer Society, as announced in January 2025. OR-449 is a first-in-class, orally available inhibitor of the orphan nuclear receptor steroidogenic factor-1 (SF-1, NR5A1), a validated target in ACC—a rare and difficult-to-treat adrenal gland cancer. The U.S. FDA has granted OR-449 Rare Pediatric Disease Designation (RPDD) to support its expedited development for pediatric ACC. Additionally, Orphagen has secured a $10.2 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to fund its IND application and a Phase I trial in adults with ACC. The grant spans three years and requires Orphagen to raise matching funds. Pembrolizumab, a widely approved PD-1 checkpoint inhibitor, is under evaluation in a Phase II trial for patients with advanced ACC. The trial, sponsored by Memorial Sloan Kettering Cancer Center, is currently in the 'active, not recruiting' phase. EO2401, a novel microbiome-based therapeutic vaccine developed by Enterome, was aimed at treating solid tumors such as glioblastoma and ACC. However, in November 2024, its Phase I/II SPENCER trial was terminated due to strategic considerations. This development marks a setback in the search for innovative treatments targeting ACC. The anticipated launch of these emerging adrenocortical carcinoma therapies are poised to transform the adrenocortical carcinoma market landscape in the coming years. As these cutting-edge adrenocortical carcinoma therapies continue to mature and gain regulatory approval, they are expected to reshape the adrenocortical carcinoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about new treatment for adrenocortical carcinoma, visit @ Adrenocortical Carcinoma Management Recent Developments in the Adrenocortical Carcinoma Market In April 2025, Cytovation announced that it had raised NOK62 million (USD 6 million) largely from existing investors, led by Sandwater. These funds will be used to advance CY-101 into a multi-national Phase II clinical trial in patients with ACC. announced that it had raised NOK62 million (USD 6 million) largely from existing investors, led by Sandwater. These funds will be used to advance CY-101 into a multi-national Phase II clinical trial in patients with ACC. In November 2024, the status of the Phase I/II SPENCER study was updated to 'terminated,' with the reason cited as a strategic decision. This termination represents a setback in the emerging prospects for developing therapies for ACC. Adrenocortical Carcinoma Overview Adrenocortical carcinoma (ACC) is a rare and aggressive cancer that originates in the cortex of the adrenal glands, which are located above the kidneys and are responsible for producing essential hormones such as cortisol, aldosterone, and androgens. ACC can occur at any age but is most commonly diagnosed in children under 5 and adults in their 40s and 50s. The exact causes of ACC are not well understood, but it has been associated with certain genetic syndromes, including Li-Fraumeni syndrome, Beckwith-Wiedemann syndrome, and multiple endocrine neoplasia type 1 (MEN1), which suggests a hereditary component in some cases. Symptoms of ACC can vary depending on whether the tumor is functioning (hormone-producing) or non-functioning. Functioning tumors may cause signs of hormone excess, such as Cushing's syndrome (weight gain, high blood pressure, muscle weakness, and skin changes), virilization in women (facial hair, deepened voice), or feminization in men. Non-functioning tumors may present later and often manifest as abdominal pain, a palpable mass, or symptoms related to tumor spread, such as weight loss or back pain. Diagnosis of ACC typically involves a combination of imaging studies and laboratory tests. Imaging techniques such as CT scans or MRI help identify the size, location, and potential spread of the tumor. Hormonal blood and urine tests assess whether the tumor is producing excess hormones. A definitive diagnosis is usually confirmed through histological examination of tissue obtained via biopsy or after surgical removal of the tumor. Early detection is crucial, as ACC often presents at an advanced stage and has a poor prognosis if not treated promptly. Adrenocortical Carcinoma Epidemiology Segmentation The adrenocortical carcinoma epidemiology section provides insights into the historical and current adrenocortical carcinoma patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The adrenocortical carcinoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Incident Cases of ACC Stage-specific Incident Cases of ACC Gender-specific Incident Cases of ACC Age-specific Incident Cases of ACC Download the report to understand which factors are driving adrenocortical carcinoma epidemiology trends @ Adrenocortical Carcinoma Treatment Algorithm Adrenocortical Carcinoma Report Metrics Details Study Period 2020–2034 Adrenocortical Carcinoma Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Adrenocortical Carcinoma Market Size in 2024 USD 30 Million Key Adrenocortical Carcinoma Companies GlaxoSmithKline, Bristol Myers Squibb, Merck, Cytovation, Enterome, Orphagen Pharmaceuticals, and others Key Adrenocortical Carcinoma Therapies CY-101, OR-449, dostarlimab, nivolumab + ipilimumab, and pembrolizumab, EO2401 + Nivolumab, and others Scope of the Adrenocortical Carcinoma Market Report Adrenocortical Carcinoma Therapeutic Assessment: Adrenocortical Carcinoma current marketed and emerging therapies Adrenocortical Carcinoma current marketed and emerging therapies Adrenocortical Carcinoma Market Dynamics: Conjoint Analysis of Emerging Adrenocortical Carcinoma Drugs Conjoint Analysis of Emerging Adrenocortical Carcinoma Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Adrenocortical Carcinoma Market Access and Reimbursement Discover more about adrenocortical carcinoma drugs in development @ Adrenocortical Carcinoma Clinical Trials Table of Contents 1. Adrenocortical Carcinoma Market Key Insights 2. Adrenocortical Carcinoma Market Report Introduction 3. Adrenocortical Carcinoma Market Overview at a Glance 4. Adrenocortical Carcinoma Market Executive Summary 5. Disease Background and Overview 6. Adrenocortical Carcinoma Treatment and Management 7. Adrenocortical Carcinoma Epidemiology and Patient Population 8. Patient Journey 9. Adrenocortical Carcinoma Marketed Drugs 10. Adrenocortical Carcinoma Emerging Drugs 11. Seven Major Adrenocortical Carcinoma Market Analysis 12. Adrenocortical Carcinoma Market Outlook 13. Potential of Current and Emerging Therapies 14. KOL Views 15. Unmet Needs 16. SWOT Analysis Related Reports Adrenocortical Carcinoma Pipeline Adrenocortical Carcinoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key adrenocortical carcinoma companies, including Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis, Ipsen, Genentech, among others. Congenital Adrenal Hyperplasia Market Congenital Adrenal Hyperplasia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key congenital adrenal hyperplasia companies, including Crinetics Pharmaceuticals Inc., Diurnal Limited, Adrenas Therapeutics Inc, Neurocrine Biosciences, Spruce Biosciences, among others. Congenital Adrenal Hyperplasia Pipeline Congenital Adrenal Hyperplasia Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key congenital adrenal hyperplasia companies, including Neurocrine Biosciences, Spruce Biosciences, Adrenas Therapeutics Inc., Crinetics Pharmaceuticals, Diurnal, among others. Cushing's Syndrome Market Cushing's Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Cushing's syndrome companies including Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stero Therapeutics, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Connect with us on LinkedIn|Facebook|Twitter Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store